Bailard Inc. Purchases 6,039 Shares of AstraZeneca PLC $AZN

Bailard Inc. raised its position in AstraZeneca PLC (NASDAQ:AZN) by 4.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 149,412 shares of the company’s stock after buying an additional 6,039 shares during the quarter. Bailard Inc.’s holdings in AstraZeneca were worth $11,463,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Chapin Davis Inc. increased its stake in AstraZeneca by 3.3% in the third quarter. Chapin Davis Inc. now owns 3,795 shares of the company’s stock valued at $291,000 after acquiring an additional 120 shares during the last quarter. CoreCap Advisors LLC boosted its holdings in shares of AstraZeneca by 30.6% in the 3rd quarter. CoreCap Advisors LLC now owns 534 shares of the company’s stock valued at $41,000 after purchasing an additional 125 shares in the last quarter. Highline Wealth Partners LLC increased its stake in shares of AstraZeneca by 32.0% in the 3rd quarter. Highline Wealth Partners LLC now owns 532 shares of the company’s stock valued at $41,000 after purchasing an additional 129 shares during the last quarter. Aaron Wealth Advisors LLC raised its holdings in shares of AstraZeneca by 0.6% during the 3rd quarter. Aaron Wealth Advisors LLC now owns 21,215 shares of the company’s stock worth $1,628,000 after buying an additional 136 shares in the last quarter. Finally, Pekin Hardy Strauss Inc. lifted its position in shares of AstraZeneca by 4.2% during the 2nd quarter. Pekin Hardy Strauss Inc. now owns 3,650 shares of the company’s stock worth $255,000 after buying an additional 148 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of AstraZeneca in a research report on Friday. Jefferies Financial Group assumed coverage on shares of AstraZeneca in a research note on Monday, October 27th. They issued a “buy” rating for the company. Wall Street Zen cut shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Finally, HSBC reissued a “buy” rating and set a $108.00 price objective on shares of AstraZeneca in a report on Wednesday, December 10th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Price Performance

Shares of NASDAQ:AZN opened at $89.94 on Wednesday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.69 and a current ratio of 0.88. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $96.51. The firm has a market cap of $278.98 billion, a PE ratio of 29.88, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The firm’s fifty day moving average is $91.68 and its 200-day moving average is $83.23.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. The business had revenue of $15.19 billion during the quarter, compared to analyst estimates of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.AstraZeneca’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period last year, the company earned $2.08 EPS. Sell-side analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.